Biotech Phoenix
Contributor since: 2016
Latest Articles
AVEO Pharmacueticals: Handicapping TIVO-3
Nektar: About The Bristol Myers Deal
Why The Juno Acquisition Talks Leaked
2018 Biotech Investing Theme: Looking For Safety Plays
Did ASH Just Change The Juno Best In Class Thesis?
Watch Out Gilead, Juno's Strategy Might Just Pay Off
Progenic's Azedra SPA: 2 Dose Monte
Progenics' Azedra: A Tale Of 2 Trials
Kite-Gilead: Winners And Losers Part 2
Kite-Gilead: Winners And Losers
Inotek: No Products, No Pipeline, No Problem
XOMA: Another Ligand In The Making?
Depomed: Can Starboard Turn A Lemon Into Lemonade?
Progenics: A Look At Upcoming Azedra Data
Inotek And The Upcoming MatrX-1 Phase 3 Results
Cempra Is Dead, Long Live Cempra!
Questions Surrounding Upcoming Solithromycin FDA Advisory Committee: Part 2
Questions Surrounding Upcoming Solithromycin FDA Advisory Committee
Alnylam: Multiple Paths Forward Post Revusiran Failure
PSivida Redux: Multiple Opportunities For Value Creation
Depomed: Acquisition Target?
PSivida: Caveat Emptor On Medidur Potential
Bondholders Fiddle While Valeant Burns
Relypsa Rumble Post-Mortem - Sum Of Parts Valuation
The Relypsa Rumble, Part 1: The Bear Case